Endocrinopathy with congenital hypogonadotropic hypogonadism as a major feature

Endocrinopathy with congenital hypogonadotropic hypogonadism as a major feature (Orphanet code 181390) is a broad clinical grouping that encompasses several rare genetic endocrine disorders in which congenital hypogonadotropic hypogonadism (CHH) is a prominent clinical manifestation. In CHH, the hypothalamic-pituitary axis fails to properly stimulate the gonads due to deficient production or action of gonadotropin-releasing hormone (GnRH), leading to absent or incomplete puberty, low sex hormone levels, and impaired fertility. These conditions primarily affect the endocrine and reproductive systems, but depending on the specific underlying disorder, additional endocrine abnormalities may be present, such as adrenal insufficiency, thyroid dysfunction, or growth hormone deficiency. Key symptoms typically include absent or delayed puberty, micropenis and cryptorchidism in males, primary amenorrhea in females, reduced or absent sense of smell (anosmia or hyposmia, as seen in Kallmann syndrome — one of the best-known conditions in this group), infertility, and potentially other hormonal deficiencies. Some conditions within this category may also feature obesity, intellectual disability, or other syndromic features depending on the genetic etiology. The body systems most commonly affected include the reproductive, endocrine, and sometimes the neurological systems. Treatment is centered on hormone replacement therapy to induce and maintain secondary sexual characteristics and to support bone health and overall well-being. Sex steroid replacement (testosterone in males, estrogen and progesterone in females) is the mainstay of therapy. When fertility is desired, pulsatile GnRH therapy or gonadotropin injections (FSH and LH/hCG) can be used to stimulate gonadal function. Management of any additional endocrine deficiencies is tailored to the specific condition. Early diagnosis and treatment are important for optimizing physical development, psychological well-being, and long-term health outcomes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Endocrinopathy with congenital hypogonadotropic hypogonadism as a major feature